in this issue
EnviroTech :: R&D
EU Trails U.S. on Biotech R&D Spending, Capability is Building
October 19, 2011 | Alex Scott
Europe needs to step up its investment in biotech R&D and establish supportive regulatory policies if it is to keep pace with the U.S. in the biotech sector, says Stephan Tanda, board member for DSM and chairman of industry biotech association EuropaBio. Total biotech R&D spending by publicly traded companies in the U.S. in 2009-2010 was $17.6 billion. This compares with €3.4 billion ($4.7 billion) in Europe during the same period. Tanda made his comments speaking earlier today at The European Forum for Industrial Biotechnology (EFIB) in Amsterdam...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee